"I think this is perfect..."
Sena showed the structure. High activity. Good selectivity. But Mikhail quietly shook his head.
"It won't become a drug."
"What? Why not?"
"Look at the molecular weight. 650. Too big."
Akira approached. "You hit Lipinski's wall."
"Lipinski?"
Mikhail began explaining. "An empirical rule for oral drugs proposed by Christopher Lipinski. Called the Rule of Five."
"Five?"
"Easy to remember with multiples of five. Molecular weight under 500, LogP under 5, hydrogen bond donors under 5, hydrogen bond acceptors under 10."
Sena took notes. "Our molecule has molecular weight 650..."
"Right. To be absorbed orally, you need appropriate size."
Akira supplemented. "To be absorbed from the intestine, it must permeate cell membranes. Too big and it can't pass."
"But the activity is high!"
"Even with high activity, if it doesn't reach the body, it's meaningless," Mikhail said gently.
Sena stared at the structure. "What should I do?"
"Cut it down," Akira answered immediately. "Find unnecessary parts and reduce molecular weight."
"But where?"
Akira analyzed the structure. "This benzene ring. Essential for activity?"
"Maybe... not essential."
"Then let's remove it. Molecular weight drops by 77."
Mikhail calculated. "Still 573. Still over."
"This long alkyl chain?" Sena pointed.
"Added to increase hydrophobicity," Akira answered.
"LogP is also a problem," Mikhail pointed out. "Calculated at 5.8. Too lipophilic."
"Is high lipophilicity bad?"
"If too fat-soluble, it accumulates in adipose tissue. Becomes hard to excrete."
Akira proposed. "Shorten the alkyl chain. C8 to C4."
"Won't activity drop?"
"Might drop. But better than not becoming a drug."
Sena drew the revised version. Molecular weight 490, LogP 4.2.
"Better," Mikhail smiled. "But there are still more metrics to check."
"Hydrogen bonds?" Sena confirmed.
"3 donors, 8 acceptors. Within range."
"So this is perfect?"
"Rule of Five is just an empirical rule," Mikhail cautioned. "Passing doesn't guarantee it becomes a drug. But failing means low probability."
Akira presented another perspective. "There are antibody drugs, giant molecules."
"Right. Rule of Five is for small molecule oral drugs. Injectable drugs and biologics have different rules."
Sena understood. "Optimal properties differ by drug type."
"Exactly. That's why we decide the Target Product Profile first. Oral drug or injectable?"
"TPP..."
"Target Product Profile. The blueprint for the drug being developed," Mikhail said.
Akira looked at the structure. "Even if this modification halves activity, if absorption improves 10-fold, the in-body effect becomes 5 times better."
"Need to consider ADME as a whole," Mikhail emphasized.
"ADME?"
"Absorption, Distribution, Metabolism, Excretion."
Sena filled the notebook. "Activity alone isn't enough..."
"Activity is just the starting point," Mikhail said kindly. "Making it into a drug from there is the essence of drug design."
Akira said finally. "Lipinski's wall is the first wall. But beyond it, there are many more walls."
"We'll hit walls many times."
"Yes. But we cross them one by one. That's optimization."
Sena gazed at the structure. The molecule that seemed perfect was actually just the first step toward a drug. But just knowing that felt like big progress.
"Next, let's look at metabolic stability," Mikhail suggested.
Another wall was waiting. But this time, she felt a bit more prepared.